Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Advanced Solid Tumors × cemiplimab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 23 Melanoma 16 Neoplasm Metastasis 11 Neoplasms 10 Squamous Cell Carcinoma of Head and Neck 9 Recurrence 8 Skin Neoplasms 6 Ovarian Neoplasms 5 Carcinoma, Squamous Cell 5 Head and Neck Neoplasms 4 Carcinoma, Renal Cell 4 Carcinoma, Basal Cell 4 Triple Negative Breast Neoplasms 3 Multiple Myeloma 3 Fallopian Tube Neoplasms 3 Endometrial Neoplasms 3 Colorectal Neoplasms 3 Breast Neoplasms 3 Adenocarcinoma 3 Uterine Cervical Neoplasms 2 Urinary Bladder Neoplasms 2 Stomach Neoplasms 2 Prostatic Neoplasms 2 Lymphoma 2 Lung Neoplasms 2 Glioblastoma 2 Cutaneous Squamous Cell Carcinoma 2 Colonic Neoplasms 2 Carcinoma, Large Cell 2 Carcinoma 2

Interventions

Injections 19 Carboplatin 15 Docetaxel 13 Paclitaxel 9 Bevacizumab 9 pembrolizumab 8 Cisplatin 7 durvalumab 6 Fluorouracil 6 trifluridine tipiracil drug combination 5 tislelizumab 5 linifanib 5 Leucovorin 5 talazoparib 4 olaparib 4 Pemetrexed 4 Nivolumab 4 Itraconazole 4 Irinotecan 4 zimberelimab 3 sintilimab 3 depatuxizumab 3 atezolizumab 3 ST 1481 3 Rifampin 3 Oxaliplatin 3 Gemcitabine 3 Capecitabine 3 130-nm albumin-bound paclitaxel 3 tremelimumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04626635 2026-02-02

COMBINE-EGFR-1

Regeneron Pharmaceuticals

Phase 1/2 Recruiting

Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon ⚡